Myeloma Origin Or Derivative Patents (Class 435/372.1)
-
Patent number: 9260499Abstract: Disclosed is a peptide consisting of the identical amino acid sequence or a substantially identical amino acid sequence to the amino acid sequence depicted in SEQ ID NO:4, wherein the peptide binds to an HLA antigen and is recognized by cytotoxic T cells. The peptide of the present invention can be used in vivo or in vitro as an agent for inducing CTL, that is, cancer vaccine, and exerts therapeutic or ameliorating effects on tumors such as osteosarcoma, renal cancer, and others. The peptide of the present invention is also useful as a tumor marker directed to tumors such as sarcoma, renal cancer, and others.Type: GrantFiled: October 19, 2009Date of Patent: February 16, 2016Assignees: SAPPORO MEDICAL UNIVERSITY, SUMITOMO DAINTPPON PHARMA CO., LTD.Inventors: Noriyuki Sato, Tomohide Tsukahara, Satoshi Kawaguchi, Takuro Wada
-
Publication number: 20150099705Abstract: The present invention relates to Protoxin-II variants, polynucleotides encoding them, and methods of making and using the foregoing.Type: ApplicationFiled: October 3, 2014Publication date: April 9, 2015Inventors: Mack FLINSPACH, Alan Wickenden, Ross Fellows, Robert Neff, Yi Liu, Rebecca Hagan, Qinghao Xu
-
Patent number: 8986702Abstract: Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments, provided herein are methods for rapidly producing antibody producing organisms, tissues, cells and antibodies derived from humans, organisms, plants or cells that are genetically altered to over-express certain proteins.Type: GrantFiled: May 18, 2009Date of Patent: March 24, 2015Assignee: Taiga Biotechnologies, Inc.Inventors: Yosef Refaeli, Brian Curtis Turner
-
Patent number: 8980329Abstract: Myeloid function is enhanced by transplantation or infusion of allogeneic myeloid progenitor cells, including CMP, GMP, MEP and MKP cell subsets. Myeloid progenitors ameliorate sequelae of anemia and thrombocytopenia, and can prevent or treat gastrointestinal mucositis associated with chemotherapy, radiotherapy, and the like. The transplantation or infusion may be performed in the absence of HLA typing, and the cells may be mismatched at one or more Class I HLA loci. The transplantation may provide for treatment of ongoing disease, or prevention of disease in high risk patients.Type: GrantFiled: September 2, 2010Date of Patent: March 17, 2015Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventor: Janice Marie Brown
-
Patent number: 8822440Abstract: This document involves methods and materials related to inhibiting cyclin D polypeptide activity. For example, this document provides methods and materials that can be used to (1) identify mammals or cells in need of cyclin D polypeptide inhibition and (2) administer an agent capable of inhibiting cyclin D polypeptide activity.Type: GrantFiled: October 10, 2007Date of Patent: September 2, 2014Assignees: Mayo Foundation for Medical Education and Research, University Health NetworkInventors: Rodger E. Tiedemann, Alexander Keith Stewart, Aaron David Schimmer, Xinliang Mao
-
Patent number: 8785189Abstract: This invention relates to the culture of dendritic cells from human embryonic stem (ES) cells. Human ES cells are first cultured into hematopoietic cells by co-culture with stromal cells. The cells now differentiated into the hematopoietic lineage are then cultured with GM-CSF to create a culture of myeloid precursor cells. Culture of the myeloid precursor cells with the cytokines GM-CSF and IL-4 causes functional dendritic cells to be generated. The dendritic cells have a unique phenotype, as indicated by their combination of cell surface markers.Type: GrantFiled: April 9, 2013Date of Patent: July 22, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Igor I. Slukvin, James A. Thomson, Maksym A. Vodyanyk, Maryna E. Gumenyuk
-
Patent number: 8771971Abstract: The present invention provides simple and rapid methods for measuring the function of a desired subset of lymphocytes, for example, T cells, B cells or NK cells. In addition, the present invention provides an all-in-one kit that contains reagents which permit a rapid and reliable analysis of the functions of T cells, B cells and NK cells obtained directly from whole blood or cord blood.Type: GrantFiled: July 30, 2007Date of Patent: July 8, 2014Assignee: The Research Foundation of State University of New YorkInventor: Allen J. Norin
-
Patent number: 8741640Abstract: A method of expanding hematopoietic stem cells. Also disclosed is a method of diagnosing primary or secondary bone marrow failure syndrome. The invention further includes a method of treating primary or secondary bone marrow failure syndrome.Type: GrantFiled: November 23, 2011Date of Patent: June 3, 2014Inventors: Hong Gao, Zhenglun Zhu
-
Patent number: 8697389Abstract: The present invention relates to cell labeling and imaging using a multifunctional perfluorocarbon (PFC) nanoemulsion. In particular, the perfluorocarbon nanoemulsion containing optical nanoparticle is provided with both optical characteristics and 19F magnetic resonance characteristics, thus can be used for magnetic resonance imaging (MRI) and optical imaging (OI) simultaneously. Cell labeling and imaging using the perfluorocarbon nanoemulsion containing quantum dot nanoparticle exerted no effect on cell viability. Therefore, perfluorocarbon nanoemulsion can be applied to methods for multifunctional and effectively cell labeling and imaging.Type: GrantFiled: March 24, 2009Date of Patent: April 15, 2014Assignee: Korea Research Institute of Bioscience And BiotechnologyInventors: Bong Hyun Chung, Yong Taik Lim
-
Patent number: 8647870Abstract: A biological photoreceptor, which is a directly light-controlled ion channel, including (i) an apoprotein and (ii) a light-sensitive polyene covalently bound to the apoprotein, the polyene interacting with the apoprotein and functioning as a direct light-sensitive gate.Type: GrantFiled: April 23, 2012Date of Patent: February 11, 2014Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.Inventors: Peter Hegemann, Georg Nagel, Ernst Bamberg
-
Patent number: 8603778Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.Type: GrantFiled: July 12, 2012Date of Patent: December 10, 2013Assignee: Janssen Biotech, Inc.Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
-
Publication number: 20130288367Abstract: A method of generating a chronic myelogenic leukemia (CML) acquired chemoresistant culture model is provided. Such a method may comprise providing a naïve blast crisis CML cell line; administering/contacting the cell line with a mutation-inducing dose of imatinib; maintaining a culture of the treated cell line for a period of time until the treated cell line relapses and repopulates the culture; and determining the repopulated cell culture is a CML acquired chemoresistant cell line by detecting a BCR-ABL mutation, wherein the acquired chemoresistance is achieved by a BCR-ABL mutation.Type: ApplicationFiled: June 19, 2013Publication date: October 31, 2013Inventors: WenYong CHEN, Ravi BHATIA, Leila SU, Yate-Ching YUAN
-
Patent number: 8361797Abstract: The present invention relates to a method for culturing mammalian cells in a culture medium which is transferrin free and which contains no lipophilic or synthetic nitrogen-containing chelators. Also provided is the use of the medium and a process for providing a mammalian product by culturing cells capable of producing the product in the medium.Type: GrantFiled: July 28, 2004Date of Patent: January 29, 2013Assignee: Medimmune LimitedInventors: Matthew David Osborne, Jonathan H. Dempsey
-
Publication number: 20120315643Abstract: Provided are alternative splicing constructs and methods for their use. In particular, CD44 based alternative splicing constructs are provided that include CD44 exon 5. These alternative splicing constructs are useful in high-throughput assays for testing the effects of compounds on splicing and for achieving targeted cell death.Type: ApplicationFiled: May 31, 2012Publication date: December 13, 2012Inventors: Dayle A. Daines, Robert J. McKallip
-
Publication number: 20120276004Abstract: Provided herein are methods for determining the presence of cancer (malignant versus benign), monitoring the progression of cancer, monitoring cancer relapse, monitoring the response to cancer therapy, or cancer staging in a subject, by evaluating CD33+/HLA-DRlow, CD1430 /HLA-DRlow, CD66b+/HLA-DRlow or, CD11b+/HLA-DRlow MDSC for activation of a transcription factor. Transcription factors include, but are not limited to, STAT3, pSTAT3, HIF1?, or C/EBP?. The MDSC phenotype can be CD33+HLA-DRlowHIF1?+/STAT3+, CD14+HLA-DRlowHIF1?+/STAT3+/pSTAT3+/C/EBPb+, CD66b+HLA-DRlowHIF1?+/STAT3+/pSTAT3+/C/EBPb+, CD33+HLA-DRlowHIF1?+/STAT3+/pSTAT3+/C/EBPb+, CD11b+HLA-DRlow HIF1?+/STAT3+/pSTAT3+/C/EBPb+, or CD11b+HLA-DRlowC/EBP?+. Also provided herein are methods for inducing human MDSC from healthy donor peripheral blood mononuclear cells (PBMC) by co-culturing PBMC with human solid tumor cell lines and subsequently measuring their suppressive ability.Type: ApplicationFiled: April 27, 2012Publication date: November 1, 2012Inventors: Alan L. Epstein, Melissa G. Lechner
-
Publication number: 20120252117Abstract: The present invention is directed to a synthetic nucleic acid sequence which encodes a protein wherein at least one non-common codon or less-common codon is replaced by a common codon. The synthetic nucleic acid sequence can include a continuous stretch of at least 90 codons all of which are common codons.Type: ApplicationFiled: April 12, 2011Publication date: October 4, 2012Inventors: Richard F Selden, Allan M. Miller, Douglas A. Treco
-
Patent number: 8202699Abstract: Use of a biological photoreceptor as light-controlled ion channel for the alteration of the ion conductivity of a membrane by means of light. The photoreceptor used comprises an apoprotein and a light-sensitive polyene covalently bound to the apoprotein, said polyene interacting with the apoprotein and functioning as a light-sensitive gate.Type: GrantFiled: May 18, 2010Date of Patent: June 19, 2012Assignee: Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.Inventors: Peter Hegemann, Georg Nagel, Ernst Bamberg
-
Publication number: 20120070430Abstract: The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.Type: ApplicationFiled: April 22, 2010Publication date: March 22, 2012Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski
-
Publication number: 20120064622Abstract: The present disclosure identifies pathways, mechanisms, systems and methods to confer chemoautotrophic production of carbon-based products of interest, such as sugars, alcohols, chemicals, amino acids, polymers, fatty acids and their derivatives, hydrocarbons, isoprenoids, and intermediates thereof, in organisms such that these organisms efficiently convert inorganic carbon to organic carbon-based products of interest using inorganic energy, such as formate, and in particular the use of organisms for the commercial production of various carbon-based products of interest.Type: ApplicationFiled: October 31, 2011Publication date: March 15, 2012Applicant: GINKGO BIOWORKSInventors: CURT R. FISCHER, AUSTIN J. CHE, RESHMA P. SHETTY, JASON R. KELLY
-
Publication number: 20110305717Abstract: Cultured lysozyme-secreting myeloid dendritic cells isolated from the subepithelial dome of Peyer's patches in the small intestine are provided. The myeloid dendritic cells are used in screening methods to identify agents which interact with myeloid dendritic cells, for example, antigens, allergens, antimicrobial agents, or agents that modulate the activity of myeloid dendritic cells. The cells are also used to identify agents which bind to and/or are taken up by myeloid dendritic cells, and which can act as delivery vehicles for delivering substances of interest to myeloid dendritic cells in vivo.Type: ApplicationFiled: June 11, 2010Publication date: December 15, 2011Inventors: Jean-Pierre Gorvell, Hugues Lelouard
-
Publication number: 20110294748Abstract: The present invention relates to insulin-like growth factor 1 receptor binding peptides, polynucleotides encoding them, and methods of making and using the foregoing.Type: ApplicationFiled: May 25, 2011Publication date: December 1, 2011Inventors: Michael Diem, Karyn O'Neil
-
Publication number: 20110195455Abstract: A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.Type: ApplicationFiled: April 4, 2011Publication date: August 11, 2011Inventors: Jacqueline Benson, Jill Carton, Mark Cunningham, Yevgeniya I. Orlovsky, Robert Rauchenberger, Raymond Sweet
-
Patent number: 7968313Abstract: This invention is in the general field of recombinant expression of polypeptides in animal cell culture. More particularly, the invention concerns improved selection in cells of recombinantly engineered vectors designed to express polypeptides.Type: GrantFiled: November 6, 2009Date of Patent: June 28, 2011Assignee: Amgen Inc.Inventors: Jeffrey T. McGrew, Allison A. Bianchi
-
Publication number: 20110044958Abstract: Inflammatory cytokines e.g. IFN-? serve as initiating stimuli for MSC immunosuppressive activity in vivo. Other inflammatory cytokines, such as TNF alpha, the molecule hemoxygenase I, and TLR ligation of MSC may also provide such a response.Type: ApplicationFiled: March 16, 2009Publication date: February 24, 2011Inventors: Amelia Bartholomewq, David Polchert, Erzsebet Szilagyi
-
Publication number: 20100297090Abstract: The present invention provides a serum-free supplement which supports the growth of hematopoietic cells in culture. Also provided are a medium comprising a basal medium supplemented with the serum-free supplement of the present invention. The present invention also provides methods for culturing and for differentiating hematopoietic cells.Type: ApplicationFiled: March 22, 2010Publication date: November 25, 2010Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: John P. Daley, Barbara M. Dadey, William C. Biddle, Michelle G. Wysocki
-
Patent number: 7824869Abstract: The invention is directed to a method for altering the ion conductivity of a membrane. The method comprises inserting a biological photoreceptor into the membrane. The biological photoreceptor is configured to act as a light-controlled ion channel. The photoreceptor used comprises an apoprotein and a light-sensitive polyene covalently bound to the apoprotein, wherein the polyene interacts with the apoprotein and functions as a light-sensitive gate.Type: GrantFiled: April 11, 2003Date of Patent: November 2, 2010Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften E.V.Inventors: Peter Hegemann, Georg Nagel, Ernst Bamberg
-
Patent number: 7811815Abstract: Myeloid function is enhanced by transplantation or infusion of allogeneic myeloid progenitor cells, including CMP, GMP, MEP and MKP cell subsets. Myeloid progenitors ameliorate sequelae of anemia and thrombocytopenia, and can prevent or treat gastrointestinal mucositis associated with chemotherapy, radiotherapy, and the like. The transplantation or infusion may be performed in the absence of HLA typing, and the cells may be mismatched at one or more Class I HLA loci. The transplantation may provide for treatment of ongoing disease, or prevention of disease in high risk patients.Type: GrantFiled: November 8, 2005Date of Patent: October 12, 2010Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventor: Janice Marie Brown
-
Patent number: 7794977Abstract: The invention relates to means and methods for regulating gene expression and production of proteinaceous molecules. The invention provides a method for producing a proteinaceous molecule in a cell comprising selecting a cell for its suitability for producing the proteinaceous molecule, providing a nucleic acid encoding the proteinaceous molecule with a nucleic acid comprising a STAR (STabilizing Anti-Repression) sequence, expressing the resulting nucleic acid in the cell and collecting the proteinaceous molecule. Providing at least one STAR sequence to a nucleic acid encoding a proteinaceous molecule will enhance production (yield) of the proteinaceous molecule by a host cell, increase the proportion of host cells with acceptable expression levels, and/or increase stability of a gene expression level.Type: GrantFiled: July 31, 2007Date of Patent: September 14, 2010Assignee: Chromagenics B.V.Inventors: Arie P. Otte, Arthur L. Kruckeberg, David P. E. Satijn
-
Patent number: 7767410Abstract: Acute myeloid leukemia stem cells (AMLSC) are identified. The cells can be prospectively isolated or identified from patient samples, and are shown to possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation, and in cancer diagnosis.Type: GrantFiled: December 7, 2007Date of Patent: August 3, 2010Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Irving L. Weissman, Naoki Hosen
-
Publication number: 20100144685Abstract: This document involves methods and materials related to inhibiting cyclin D polypeptide activity. For example, this document provides methods and materials that can be used to (1) identify mammals or cells in need of cyclin D polypeptide inhibition and (2) administer an agent capable of inhibiting cyclin D polypeptide activity.Type: ApplicationFiled: October 10, 2007Publication date: June 10, 2010Inventors: Rodger E. Tiedemann, Alexander Keith Stewart, Aaron David Schimmer, Xinliang Mao
-
Publication number: 20100120750Abstract: Disclosed are methods for inducing polyploidization of megakaryocyte cells and for promoting differentiation of megakaryocyte cells into platelet-producing cells. The methods may be utilized for treating blood and bone marrow diseases and disorders in a subject in need thereof and for identifying agents for treating blood and bone marrow diseases and disorders.Type: ApplicationFiled: November 6, 2009Publication date: May 13, 2010Applicant: Northwestern UniversityInventors: John D. Crispino, Qiang Wen, Zan Huang, Andrew M. Stern, Robert J. Gould
-
Patent number: 7713688Abstract: The invention provides compositions and methods for cell separation. These reagents and techniques specifically agglutinate cells via surface antigen recognition and can be used to recover even rare cell types in high yield.Type: GrantFiled: January 26, 2007Date of Patent: May 11, 2010Assignee: BioE, LLCInventor: Daniel P. Collins
-
Publication number: 20100104510Abstract: The invention provides methods and compositions employing hybrid molecules of a synthetic molecule and antibody or antibody fragment comprising a selenocysteine residue, wherein the synthetic molecule is covalently linked to the antibody or antibody fragment at the selenocysteine residue. The invention also provides a composition comprising a hybrid molecule as described above and a pharmaceutically acceptable carrier. The invention further provides for methods of making the hybrid molecules, and methods of using the hybrid molecule described above to inhibit cell surface receptor binding.Type: ApplicationFiled: September 30, 2009Publication date: April 29, 2010Applicants: ServicesInventors: Christoph Rader, Thomas Hofer, Terrence Burke, JR., Joshua Thomas
-
Patent number: 7691605Abstract: This invention relates to the general field of recombinant expression of polypeptides in animal cell culture. More particularly, the invention concerns improved selection in cells of recombinantly engineered vectors designed to express polypeptides.Type: GrantFiled: September 20, 2002Date of Patent: April 6, 2010Assignee: Immunex CorporationInventors: Jeffrey T. McGrew, Allison A. Bianchi
-
Publication number: 20090142841Abstract: Vectors capable of stably integrating a transgene in the genome of a non-dividing cell or of a slowly-dividing cell, said vector comprising or expressing at least one immortalization molecule and cells immortalized with said vectors.Type: ApplicationFiled: August 28, 2008Publication date: June 4, 2009Inventors: Teresa Occhiodoro, Patrick Salmon, Didier Trono
-
Publication number: 20090110678Abstract: The invention provides methods of treating bone cancer, particularly metastatic bone cancer, by administering an IGF-IR antagonist and/or a PDGFR? antagonist. The invention also provides antibodies that bind to human PDGFR? and neutralize activation of the receptor. The invention further provides a methods for neutralizing activation of PDGFR?, and a methods of treating a mammal with a neoplastic disease using the antibodie alone or in combination with other agents.Type: ApplicationFiled: June 19, 2006Publication date: April 30, 2009Applicants: ImClone Systems Incorporated, University of WashingtonInventors: Dale L. Ludwig, Stephen R. Plymate
-
Publication number: 20090068109Abstract: The present invention relates to at least one novel anti-MCP-1 antibody, including isolated nucleic acids that encode at least one anti-MCP-1 antibody, MCP-1, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: ApplicationFiled: November 19, 2007Publication date: March 12, 2009Inventors: Anuk Das, Raymond Sweet, Ping Tsui, Michael Bardroff
-
Publication number: 20090068178Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.Type: ApplicationFiled: January 31, 2008Publication date: March 12, 2009Applicant: Genentech, Inc.Inventors: Craig Crowley, Frederic J. de Sauvage, Dan L. Eaton, Allen Ebens, JR., Kristi Elkins, Jo-Anne S. Hongo, Jagath Reddy Junutula, Andrew Polson, Sarajane Ross, Victoria Smith, Richard L. Vandlen, Bing Zheng
-
Publication number: 20090061513Abstract: A method of cell seeding is provided, which comprises the steps of: providing a cell sample; seeding at least one cell of said cell sample into at least one well of a microplate comprising at least 5 wells/cm2. Also provided is a method of cell cultivation comprising the steps of: seeding at least one cell into a microplate using the method of cell seeding; incubating the microplate; and analyzing the contents of at least one well of the microplate.Type: ApplicationFiled: May 14, 2008Publication date: March 5, 2009Applicant: PicoVitro ABInventors: Helene Andersson Svahn, Sara Lindstrom
-
Patent number: 7491530Abstract: The present invention provides in one aspect novel fusion partner cells that ectopically express one or more genes that alter the phenotype of a hybrid cell made from a fusion of the fusion partner cell and a fusion cell, hybrid cell lines produced using the fusion partner cells. The invention in another aspect provides antibodies produced by certain hybrid cell lines, and compositions containing one or a combination of such antibodies or antigen-binding fragments thereof. The invention also provides in another aspect methods of using the antibodies or antigen-binding fragments thereof for diagnosis and treatment of diseases characterized by the antigens specifically bound by the antibodies.Type: GrantFiled: December 18, 2002Date of Patent: February 17, 2009Assignee: Whitehead Institute for Biomedical ResearchInventors: Scott K. Dessain, Robert A. Weinberg
-
Publication number: 20090011468Abstract: The present invention relates to the production of proteins in a cell or host cell. The invention uses a TRAnscription Pause (TRAP) sequence to enhance a protein expression characteristic of a protein expression unit. The TRAP sequence is thought to prevent, at least in part, formation of antisense RNA or to, at least in part, prevent transcription to enter the protein expression unit. In one embodiment, the invention provides a method for expression of at least one protein of interest in a cell comprising providing the cell with at least one protein expression unit that comprises a promoter functionally linked to an open reading frame encoding at least one protein of interest, characterized in that the protein expression unit further comprises at least one TRAP sequence and wherein the TRAP sequence is functionally located downstream of the open reading frame and at least in part prevents formation of antisense RNA.Type: ApplicationFiled: July 11, 2008Publication date: January 8, 2009Applicant: Chromagenics B.V.Inventors: Arie Pieter Otte, Henricus Johannes Maria Van Blokland
-
Publication number: 20080312172Abstract: The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: ApplicationFiled: October 30, 2007Publication date: December 18, 2008Inventors: Jill Giles-Komar, David Knight, David Peritt, Mohit Trikha
-
Patent number: 7449340Abstract: The present invention relates to a method for the early diagnosis of cancer in a subject, which is based on determination of the relative fraction of microorganisms derived from the feces of the subject, as compared to the total count of microorganisms in the same of corresponding sample. This relation has been found to be indicative of the presence or absence of cancer in said subject. After isolating at least one of the microorganisms from the fecal sample to form a so-called diagnostic sample, and incubating, for a sufficient time, the diagnostic sample with cancer cells. The microorganism being in an amount corresponding to its relative fraction in the original fecal sample, the cancerolytic activity of the microorganism/s is indicative to the presence or absence of cancer cells in the subject. The cancerolytic activity is expressed by terms of a tumor cell necrosis index (TCNI).Type: GrantFiled: August 9, 2001Date of Patent: November 11, 2008Assignee: Era-Massis, Inc.Inventors: Gil Tenne, Mark L. Levitt, Anahit Karapetian
-
Patent number: 7439037Abstract: Use of aminoglycoside resistance gene product for achieving high-density growth of animal cells.Type: GrantFiled: September 26, 2002Date of Patent: October 21, 2008Assignees: Lonza Biologics PLCInventors: Mohamed Al-Rubeai, Angelo Perani, Andy Racher, John Birch
-
Patent number: 7387873Abstract: There is provided a human myeloma cell tine for use in a method for producing a human monoclonal antibody.Type: GrantFiled: January 3, 2003Date of Patent: June 17, 2008Assignee: Cambridge University Technical Services Ltd.Inventor: Abraham Karpas
-
Publication number: 20080131930Abstract: The invention relates to means and methods for regulating gene expression and production of proteinaceous molecules. The invention provides a method for producing a proteinaceous molecule in a cell comprising selecting a cell for its suitability for producing the proteinaceous molecule, providing a nucleic acid encoding the proteinaceous molecule with a nucleic acid comprising a STAR (STabilizing Anti-Repression) sequence, expressing the resulting nucleic acid in the cell and collecting the proteinaceous molecule. Providing at least one STAR sequence to a nucleic acid encoding a proteinaceous molecule will enhance production (yield) of the proteinaceous molecule by a host cell, increase the proportion of host cells with acceptable expression levels, and/or increase stability of a gene expression level.Type: ApplicationFiled: July 31, 2007Publication date: June 5, 2008Applicant: ChromaGenics B.V.Inventors: Arie P. Otte, Arthur L. Kruckeberg, David P.E. Satijn
-
Publication number: 20080014636Abstract: An inducer of cytotoxic T cells comprising as an active ingredient a protein which comprises the same or substantially the same amino acid sequence as that shown in SEQ ID NO: 2, or a peptide derived from the protein above is provided.Type: ApplicationFiled: September 19, 2003Publication date: January 17, 2008Inventors: Noriyuki Sato, Tomohide Tsukahara, Yuki Nabeta, Satoshi Kawaguchi, Hideyuki Ikeda, Takuro Wada, Toshihiko Yamashita
-
Patent number: 7267965Abstract: The invention relates to means and methods for regulating gene expression and production of proteinaceous molecules. The invention provides a method for producing a proteinaceous molecule in a cell comprising selecting a cell for its suitability for producing the proteinaceous molecule, providing a nucleic acid encoding the proteinaceous molecule with a nucleic acid comprising a STAR (STabilizing Anti-Repression) sequence, expressing the resulting nucleic acid in the cell and collecting the proteinaceous molecule. Providing at least one STAR sequence to a nucleic acid encoding a proteinaceous molecule will enhance production (yield) of the proteinaceous molecule by a host cell, increase the proportion of host cells with acceptable expression levels, and/or increase stability of a gene expression level.Type: GrantFiled: December 14, 2004Date of Patent: September 11, 2007Assignee: Chromagenics B.V.Inventors: Arie P. Otte, Arthur L. Kruckeberg, David P. E. Satijn
-
Patent number: 7238525Abstract: The chimeric Bcr-Abl oncoprotein is the molecular hallmark of chronic myelogenous leukemia (CML). In the cytoplasm, the protein transduces a growth signal that is responsible for overexpansion of cells. In the nucleus, the protein induces apoptosis. The invention is a method of treating cancer/killing Bcr-Abl expressing cells by inducing the translocation of Bcr-Abl to the nucleus to activate the apoptotic pathway in cancer cells.Type: GrantFiled: June 29, 2001Date of Patent: July 3, 2007Assignee: The Regents of the University of CaliforniaInventors: Jean Y. J. Wang, Paolo Vigneri
-
Patent number: 7220559Abstract: This invention provides: a heteromyeloma, other than B6B11, capable of producing a trioma when fused with a human lymphoid cell, wherein the trioma is capable of producing a monoclonal antibody-secreting tetroma when fused with a second, antibody-secreting human lymphoid cell; a trioma fusion partner which does not produce antibody, obtained by fusing a heteromyeloma which does not produce antibody with a human lymphoid cell; a monoclonal antibody-secreting tetroma, obtained by fusing a trioma which does not produce antibody with an antibody-secreting human lymphoid cell; a method of producing a monoclonal antibody that specifically recognizes an antigen associated with a condition; a method of identifying an antigen associated with a condition using the trioma fusion partner; a method of diagnosing a condition using the trioma fusion partner; a method for preventing a condition; and compositions and therapeutic compositions comprising monoclonal antibodies produced using the trioma fusion partner.Type: GrantFiled: January 23, 2001Date of Patent: May 22, 2007Assignee: The Trustees of Columbia University in the City of New YorkInventor: Ilya Trakht